Research Signal – Source date 2024-10-21
Cellular senescence is a state in which a cell permanently stops dividing but remains alive and metabolically active. These cells can help with development, wound healing and tissue repair. They can also release inflammatory signals that alter nearby cells. The same activity that helps coordinate a local repair response may become harmful if it persists or spreads through tissue.
A review published on October 21, 2024, brings together evidence linking senescence to atherosclerosis, heart failure and metabolic disease. The findings are not equally developed across these conditions, and the treatment ideas remain largely based on laboratory and animal research. Understanding why senescent cells behave differently matters both for interpreting the disease evidence and for judging whether removing them could help.
A stopped cell can still change its surroundings
Senescent cells often have a flattened shape and changes in gene activity. They can resist cell death through increased activity of anti-apoptotic proteins. Many also release a mix of cytokines, chemokines, growth factors and enzymes called the senescence-associated secretory phenotype, or SASP.
Some SASP factors act back on the senescent cell itself. Signals such as the inflammatory molecule IL-6 can help maintain growth arrest, promote inflammation and reshape the surrounding matrix. Other secretions affect nearby cells, potentially promoting inflammation or DNA damage. In some circumstances, neighboring healthy cells can enter senescence too, adding more SASP-producing cells to the local environment. Senescent cells may also package signaling molecules into extracellular vesicles, which can carry proteins, lipids and genetic material between cells.
This signaling is not inherently destructive. During repair, secreted factors can recruit immune cells or limit fibrosis. The concern is that a persistent inflammatory secretome may turn a temporary response into a chronic one. How often that transition occurs in human disease, and which secretions drive it, remain open questions.
Metabolic stress can reach senescence by different routes
High glucose has been linked to senescence in endothelial cells, smooth-muscle cells and fibroblasts. In retinal endothelial cells, studies summarized by the review connect high glucose with oxidative stress, reduced nitric oxide and increased activity of arginase-1. Blocking arginase or an oxidant-producing enzyme, or supplying nitric oxide, prevented senescence in experimental work. These observations suggest several connected routes from glucose stress to cell-cycle arrest; they do not establish one pathway across all tissues.
Excess lipids can stress cells that cannot safely store or process them. In the presence of reactive oxygen species, lipids may be oxidized, contributing to mitochondrial damage or stress in the endoplasmic reticulum. The review also describes signaling effects from particular lipid molecules: ceramide can increase the cell-cycle inhibitor p21, while the related molecule sphingosine-1-phosphate has been associated with opposing effects. Palmitate, a saturated fatty acid, has been shown to induce senescence in vascular cells. These routes differ in their starting point and may produce different effects on a cell’s secretions.
Mitochondrial dysfunction offers another route. A form called mitochondrial dysfunction-associated senescence, or MiDAS, is linked to a lower NAD+/NADH ratio and activation of AMPK and p53. Its secretome differs from other senescent-cell patterns, including the absence of the IL-1–NF-κB component described in the review. The change in metabolism may help drive growth arrest, but whether metabolic shifts initiate senescence or follow it is not settled. A single label, then, does not guarantee a uniform cell state or a uniform effect on neighboring tissue.
The artery evidence is further along than the heart evidence
For atherosclerosis, the review describes senescence markers in endothelial cells and vascular smooth-muscle cells in plaques and vessel walls, as well as observations in macrophages. Experimental studies have tested senolytic drugs and genetic removal of cells marked by p16. Some reported improved vessel function, reduced calcification or changes in plaque burden and stability. Results have varied, however, including when similar removal strategies were used. Macrophage findings are especially difficult to interpret because common senescence markers can produce misleading positives in these cells.
The evidence for heart failure with preserved ejection fraction (HFpEF) is narrower. In one mouse model, diastolic dysfunction appeared alongside aortic endothelial inflammation and senescence, but HFpEF developed when the animals also faced a high-fat diet and added salt. This points to senescence as a possible contributor under combined stress, rather than a sufficient cause on its own. A separate rat model of cardiometabolic HFpEF also showed senescence-related observations, but the review notes that only a small number of studies had examined the question.
Diabetic cardiomyopathy is likewise unresolved. Diabetes changes cardiac metabolism and can expose tissue to persistent excess sugar and lipids, but it remains unclear whether these stresses cause cardiomyocyte senescence in a way that drives the disease. The review describes senescence and oxidative stress in cardiac progenitor cells from people with type 2 diabetes, and preclinical work in which clearing these cells improved their function and cardiac measures in mice. Those findings do not establish that senolytic treatment improves heart outcomes in patients.
Removing cells and quieting their signals are different strategies
Senolytics aim to kill senescent cells by disrupting the survival pathways that help some of them resist apoptosis. Dasatinib combined with quercetin and the drug navitoclax are examples discussed in the review. In animal models, these approaches have reduced senescence burden or improved selected measures in atherosclerosis, heart failure models and metabolic disease. Sensitivity varies by cell type, and senescent cells are not all equally vulnerable.
Senostatics, also called senomorphics, aim to reduce the SASP without killing the cell. They target pathways involved in producing or releasing inflammatory factors. This could preserve cells whose presence supports repair while limiting harmful local signaling. But the approach has its own difficulty: SASP composition changes by cell type and circumstance, and drugs that suppress it can affect other processes or weaken immune responses. Neither strategy can be assumed to selectively act on harmful senescence in every tissue.
Finding the right cells is part of the treatment problem
There is no single specific marker that identifies every senescent cell in living tissue. Researchers combine indicators such as p16, p21, p53 activity and senescence-associated beta-galactosidase (SAβG), but each has limitations. SAβG can stain cells with high lysosomal content even when they are proliferating; the review highlights macrophages as a particular concern. That makes both estimates of senescent-cell burden and the choice of a treatment target difficult.
Safety also depends on which cells are removed and how. Navitoclax has dose-related platelet toxicity, while dasatinib can cause low platelet counts and has been associated with possible cardiac toxicity. Removing useful senescent cells could interfere with healing; in animal studies, eliminating certain senescent endothelial cells worsened pulmonary hypertension or led to liver fibrosis. Long-term effects, ideal dosing and how dead cells are cleared also remain unsettled. These concerns make targeted action more important than simply reducing a marker count.
What targeted treatment could mean for heart and metabolic disease
Treatments tailored to harmful senescent cells or their persistent signals could one day help protect diseased arteries or improve metabolic function while preserving cells that support repair. Reaching that capability depends on identifying which cells matter in each condition, showing that intervention improves outcomes in people, and controlling risks such as platelet toxicity, immune effects and impaired healing. The review makes this a plausible research direction, not an established clinical benefit.
Key Sources
- Primary source: Cell senescence in cardiometabolic diseases.
DOI or Journal Page · Review or Meta-Analysis · 2024-10-21
Keep exploring